Management information from Tripep

The Board of Tripep’s has come to a mutual understanding with Tripep’s CEO Jan Nilsson that he will leave the Company. According to contract Jan Nilsson has employment with the Company up to September 30th 2009. During a transitional stage Anders Vahlne, Head of Research and Development, will be the acting CEO after Jan Nilsson. The transition from Jan Nilsson to Anders Vahlne will take place after consultations between Jan Nilsson and the Board. Anders Vahlne will receive no extra remuneration from Tripep.



For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, Mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se






About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending
technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website:
www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take
precedence.